Table 4. Prognostic implication of AEs on OS in Chinese patients with mRCC treated with sorafenib.

Adverse events	Number of patients	Median OS (95% CI) (Months)	p value
Hand-foot skin reaction
Yes	155	25.5 (16.0, 35.1)	0.028
No	101	16.7 (11.8, 21.7)
Alopecia
Yes	87	41.5 (25.1, 58.0)	< 0.001
No	169	18.4 (15.2, 21.6)
Rash
Yes	63	37.7 (17.2, 58.2)	0.018
No	193	20.9 (18.0, 23.9)
Diarrhea
Yes	99	28.7 (17.9, 39.5)	0.047
No	157	20.1 (13.4, 26.8)
Constipation
Yes	33	22.8 (15.7, 29.8)	0.887
No	223	22.1 (20.2, 24.1)
Nausea
Yes	49	20.1 (18.4, 25.0)	0.083
No	207	23.7 (18.7, 30.4)
Vomiting
Yes	19	15.2 (11.1, 19.3)	0.011
No	237	24.7 (17.4, 31.8)
Hypertension
Yes	55	40.1 (28.3, 53.5)	0.019
No	201	21.1 (17.9, 24.2)
Angina pectoris and myocardial infarction
Yes	3	3.6 (1.3, 12.8)	0.217
No	253	22.3 (18.2, 26.5)
Anemia
Yes	41	19.9 (17.9, 24.2)	0.126
No	215	23.7 (18.9, 28.8)
Leukopenia
Yes	7	21.9 (18.2, 26.5)	0.773
No	249	22.6 (18.4, 27.3)
Thrombocytopenia
Yes	4	33.3 (17.3, 55.8)	0.527
No	252	22.1 (18.5, 25.5)
Mucositis
Yes	46	25.5 (9.8, 41.3)	0.214
No	210	21.9 (16.1, 27.6)
Liver dysfunction
Yes	39	31.1 (16.8, 45.5)	0.109
No	217	22.0 (18.3, 25.7)
Renal dysfunction
Yes	18	16.9 (9.4, 24.5)	0.027
No	238	24.6 (17.3, 32.0)
Albuminuria
Yes	28	18.4 (15.5, 21.3)	0.046
No	228	24.6 (19.9, 29.4)
Gingival hemorrhage
Yes	54	24.2 (16.9, 31.6)	0.173
No	202	21.7 (16.9, 26.3)
Stool hemorrhage
Yes	43	22.9 (16.7, 29.9)	0.775
No	213	22.3 (18.5, 26.1)
Hemoptysis
Yes	27	22.1 (12.8, 31.2)	0.459
No	229	23.7 (18.8, 28.7)
Fatigue
Yes	91	20.8 (15.9, 25.8)	0.108
No	165	25.1 (18.4, 31.3)
Weight loss
Yes	23	17.5 (14.9, 20.1)	0.027
No	233	24.9 (16.9, 32.9)

AEs, adverse events; mRCC; metastatic renal cell carcinoma; OS, overall survival.